Kymera Therapeutics, Inc. (KYMR)
131.73
+3.61
(+2.82%)
USD |
NASDAQ |
Nov 06, 16:00
131.70
-0.03
(-0.02%)
After-Hours: 20:00
Kymera Therapeutics Shareholders Equity (Quarterly) : 1.615B for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 1.615B |
| June 30, 2026 | 1.509B |
| March 31, 2026 | 1.540B |
| December 31, 2025 | 1.580B |
| September 30, 2025 | 946.26M |
| June 30, 2025 | 971.48M |
| March 31, 2025 | 786.23M |
| December 31, 2024 | 835.62M |
| September 30, 2024 | 892.93M |
| June 30, 2024 | 684.92M |
| March 31, 2024 | 711.20M |
| December 31, 2023 | 394.97M |
| September 30, 2023 | 395.54M |
| June 30, 2023 | 435.43M |
| Date | Value |
|---|---|
| March 31, 2023 | 462.00M |
| December 31, 2022 | 490.15M |
| September 30, 2022 | 512.88M |
| June 30, 2022 | 397.95M |
| March 31, 2022 | 428.72M |
| December 31, 2021 | 459.64M |
| September 30, 2021 | 483.14M |
| June 30, 2021 | 258.10M |
| March 31, 2021 | 275.25M |
| December 31, 2020 | 283.89M |
| September 30, 2020 | 294.68M |
| June 30, 2020 | 104.04M |
| March 31, 2020 | |
| December 31, 2019 | 34.67M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Intellia Therapeutics, Inc. | 613.09M |
| Twist Bioscience Corp. | 445.74M |
| Beam Therapeutics, Inc. | 952.67M |
| C4 Therapeutics, Inc. | 228.17M |
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.767B |
| Total Liabilities (Quarterly) | 152.74M |
| Debt to Equity Ratio | 0.0474 |
| Current Ratio | 11.13 |
| Net Debt Paydown Yield | 0.02% |